Stable HEK-293 Cell Lines for AAV Production via Targeted Integration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing adeno-associated virus (AAV) face challenges such as poor scalability, reproducibility, high manufacturing costs, and instability due to random integration of nucleotide sequences, leading to inefficient and costly production processes.
Innovation Solution
Development of stable mammalian host cells with targeted integration (TI) and transposon-mediated genomic integration strategies, incorporating specific exogenous nucleic acid sequences for AAV production, including recombination recognition sequences and selection markers, to enhance stability and efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If transient transfection of production cell lines with plasmids containing AAV genes is used, then AAV production is achieved, but scalability and reproducibility are poor
Solution Approach 1:
The patent applies preliminary action by pre-integrating AAV genes and adenoviral helper genes into the host cell genome before production. This creates stable producer cell lines that consistently express viral proteins, eliminating the variability associated with transient transfection and significantly improving manufacturing reproducibility while maintaining high productivity.
Solution Approach 2:
The patent changes the fundamental parameter of gene delivery from transient transfection to stable genomic integration. This parameter change transforms the production system from one with high variability to one with consistent, reproducible expression of AAV and helper proteins across cell generations.
2Productivity
If random integration of nucleotide sequences is used, then production cell lines can be generated, but gene expression and cell growth phenotypes become unstable
Solution Approach 1:
The patent uses a specific genomic locus as an intermediary integration site. By targeting a predetermined safe harbor locus rather than allowing random integration, the system achieves both stable cell growth and consistent gene expression. The intermediary locus serves as a controlled entry point that maintains genomic stability while enabling reliable protein production.
3Productivity
If adherent cells are used for virus production, then production can be achieved, but scale-up options are limited and manufacturing costs increase
Solution Approach 1:
The patent enables dynamic scaling by creating stable cell lines that can be adapted to different culture formats. The integrated genome maintains expression stability whether cells are cultured in adherent format at small scale or suspended in bioreactors at large scale, providing flexible scale-up options that reduce manufacturing complexity and cost.
4Productivity
If serum is used in manufacturing platforms, then cell growth is supported, but viral particles become contaminated increasing downstream processing costs
Solution Approach 1:
The patent extracts and eliminates serum from the manufacturing process by using stable cell lines that can thrive in serum-free conditions. The integrated genomic constructs maintain robust expression of AAV and helper proteins without requiring serum supplementation, thereby preventing contamination of viral particles with serum components and reducing downstream purification costs.
Data Source
AI summary
The presently disclosed subject matter relates to compositions and methods for the generation of stable human embryonic kidney-293 (HEK-293) cell lines for adeno-associated virus (AAV) production.